Pfizer Slides as Investors Appear to Reassess Near-Term Growth Catalysts

Pfizer (PFE) is down 3.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The immediate catalyst is unclear, but the sell-off appears tied to continued skepticism around Pfizer’s near-term growth outlook rather than a single negative headline. This could be because investors are still balancing encouraging pipeline updates against competitive pressure in obesity, upcoming patent-expiration risks, and limited room above recent valuation targets.

Details:

Pfizer’s recent obesity data showed strong mid-stage weight-loss results for berobenatide and supported plans for a broad Phase 3 program, but the market still views the company as trailing the leading obesity players.

A recent analyst rating change became less bullish than it may first appear: the stock was moved up on valuation grounds while the price target stayed around current trading levels, suggesting expectations for major near-term upside remain modest.

Pfizer reaffirmed its 2026 guidance in early May and has continued to highlight pipeline milestones, so today’s decline does not appear to be driven by a fresh guidance cut or major operational warning.

Company filings and recent investor materials continue to point to loss-of-exclusivity and product-erosion pressures over the next several years, which may keep investors cautious even when pipeline news is constructive.

Sources:

Pfizer, SEC, Reuters, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$PFE Insider Trading Activity

$PFE insiders have traded $PFE stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $PFE stock by insiders over the last 6 months:

JENNIFER B. DAMICO (SVP & Controller) sold 2,000 shares for an estimated $51,400

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$PFE Hedge Fund Activity

We have seen 1,503 institutional investors add shares of $PFE stock to their portfolio, and 1,382 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FISHER ASSET MANAGEMENT, LLC added 53,012,321 shares (+102.0%) to their portfolio in Q1 2026, for an estimated $1,480,104,002
NORGES BANK removed 20,119,761 shares (-21.5%) from their portfolio in Q4 2025, for an estimated $500,982,048
PACER ADVISORS, INC. removed 17,574,851 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $437,613,789
JANUS HENDERSON GROUP PLC added 7,489,189 shares (+577.5%) to their portfolio in Q4 2025, for an estimated $186,480,806
GOLDMAN SACHS GROUP INC added 7,058,154 shares (+17.6%) to their portfolio in Q1 2026, for an estimated $197,063,659
VANGUARD GROUP INC added 7,031,162 shares (+1.3%) to their portfolio in Q4 2025, for an estimated $175,075,933
ACADIAN ASSET MANAGEMENT LLC added 6,629,451 shares (+374.1%) to their portfolio in Q1 2026, for an estimated $185,094,271

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$PFE Government Contracts

We have seen $1,463,966 of award payments to $PFE over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

PFIZER VACCINES STORAGE AND ROTATION CONTRACT: $820,406
4569494415!PROCARDIA XL 30 MG TABLET 100S: $24,723
4568676827!HEXTEND 6%-LACT ELEC BAG 500ML: $11,164

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$PFE Congressional Stock Trading

Members of Congress have traded $PFE stock 4 times in the past 6 months. Of those trades, 1 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $PFE stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 3 times. They made 1 purchase worth up to $15,000 on 02/10 and 2 sales worth up to $30,000 on 03/13, 12/19.
REPRESENTATIVE J. FRENCH HILL sold up to $250,000 on 12/31.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$PFE Price Targets

Multiple analysts have issued price targets for $PFE recently. We have seen 11 analysts offer price targets for $PFE in the last 6 months, with a median target of $27.0.

Here are some recent targets:

Trung Huynh from RBC Capital set a target price of $25.0 on 06/10/2026
Geoff Meacham from Citigroup set a target price of $27.0 on 04/29/2026
Jin Zhang from CICC set a target price of $33.0 on 04/16/2026
Michael Yee from UBS set a target price of $27.0 on 04/13/2026
Terence Flynn from Morgan Stanley set a target price of $28.0 on 04/10/2026
Jason Gerberry from B of A Securities set a target price of $26.0 on 04/09/2026
Vamil Divan from Guggenheim set a target price of $36.0 on 03/24/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.